You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Medtronic
Johnson and Johnson
Harvard Business School
McKinsey

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,462,625

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,462,625
Title:Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
Abstract: GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: ##STR00001## wherein A, Q, R.sub.1, R.sub.2, R.sub.3a, R.sub.3b, R.sub.4, R.sub.5, R.sub.6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.
Inventor(s): Zhu; Yun-Fei (San Diego, CA), Chen; Chen (San Diego, CA), Tucci; Fabio C. (San Diego, CA), Guo; Zhiqiang (San Diego, CA), Gross; Timothy D. (San Diego, CA), Rowbottom; Martin (La Jolla, CA), Struthers; R. Scott (Encinitas, CA)
Assignee: Neurocrine Biosciences, Inc. (San Diego, CA)
Application Number:11/520,022
Patent Claims: 1. A compound having the following structure: ##STR02976## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl aryl or substituted aryl; R.sub.4 is aryl, substituted aryl, heterocycle or substituted heterocycle; R.sub.5 is hydrogen or lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl.

2. A compound according to claim 1, wherein R.sub.3a is at each occurrence independently hydrogen, alkyl or aryl.

3. A compound according to claim 2, wherein R.sub.3a is at each occurrence hydrogen, methyl, isobutyl, cyclohexyl or phenyl.

4. A compound according to claim 1, wherein R.sub.3b is at each occurrence hydrogen.

5. A compound according to claim 4, wherein R.sub.4 is substituted phenyl.

6. A compound according to claim 5, wherein R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy.

7. A compound according to claim 1, wherein R.sub.5 is hydrogen or lower alkyl.

8. A compound according to claim 7, wherein R.sub.5 is hydrogen or methyl.

9. A compound according to claim 1, wherein R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl.

10. A compound according to claim 9, wherein R.sub.6 is benzyl or substituted benzyl.

11. A compound according to claim 1, wherein: R.sub.3a is at each occurrence independently hydrogen, methyl, isobutyl, cyclohexyl or phenyl; R.sub.3b is at each occurrence hydrogen; R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy; R.sub.5 is hydrogen or methyl; and R.sub.6 is benzyl or substituted benzyl.

12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound having the following structure: ##STR02977## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.4 is substituted aryl or substituted heterocycle; R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl.

13. A pharmaceutical composition according to claim 12, wherein: R.sub.3a is at each occurrence hydrogen, alkyl or aryl; R.sub.3b is at each occurrence hydrogen; and R.sub.4 is substituted phenyl.

14. A pharmaceutical composition according to claim 13, wherein: R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl.

15. A pharmaceutical composition according to claim 12, wherein: R.sub.3a is at each occurrence hydrogen, methyl, isobutyl, cyclohexyl or phenyl; R.sub.3b is at each occurrence hydrogen; R.sub.4 is phenyl substituted with halogen, alkoxy, or both halogen and alkoxy; R.sub.5 is hydrogen or methyl; and R.sub.6 is benzyl or substituted benzyl.

16. A method for treating a condition selected from the group of endometriosis, polycystic ovarian disease, uterine fibroids, infertility, precocious puberty, prostatic cancer, uterine cancer, breast cancer, pituitary gonadotroph adenomas, benign prostatic hypertrophy and myoma of the uterus in a subject in need thereof comprising administering to the subject an effective amount of a compound having the following structure: ##STR02978## or a stereoisomer or pharmaceutically acceptable salt thereof, wherein: Q is a direct bond; A is O; n is 2; R.sub.1 is hydrogen or alkyl; R.sub.2 is hydrogen, alkyl or substituted alkyl; R.sub.3a and R.sub.3b are the same or different and, at each occurrence, independently hydrogen, alkyl, substituted alkyl, aryl or substituted aryl; R.sub.4 is substituted aryl or substituted heterocycle; R.sub.5 is hydrogen, lower alkyl or substituted lower alkyl; and R.sub.6 is arylalkyl, substituted arylalkyl, heteroarylalkyl or substituted heteroarylalkyl.

17. A method according to claim 16, wherein the condition is endometriosis, polycystic ovarian disease, uterine fibroids, infertility or precocious puberty.

18. A method according to claim 16, wherein the condition is endometriosis, breast cancer, uterine fibroids or benign prostatic hypertrophy.

19. A method according to claim 16, wherein the condition is endometriosis.

20. A method according to claim 16, wherein the condition is benign prostatic hypertrophy.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Express Scripts
McKinsey
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.